NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Forecast, Price & News $1.46 -0.03 (-2.01%) (As of 09:52 AM ET) Add Compare Share Share Today's Range$1.45▼$1.5250-Day Range$0.87▼$1.5752-Week Range$0.79▼$5.25Volume10,229 shsAverage Volume1.36 million shsMarket Capitalization$187.67 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Praxis Precision Medicines MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside470.5% Upside$8.50 Price TargetShort InterestHealthy2.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 4 Articles This WeekInsider TradingAcquiring Shares$10,600 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.77) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector393rd out of 965 stocksPharmaceutical Preparations Industry172nd out of 453 stocks 3.4 Analyst's Opinion Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Praxis Precision Medicines has a forecasted upside of 470.5% from its current price of $1.49.Amount of Analyst CoveragePraxis Precision Medicines has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.12% of the outstanding shares of Praxis Precision Medicines have been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Praxis Precision Medicines has recently increased by 10.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRAX. Previous Next 2.6 News and Social Media Coverage News SentimentPraxis Precision Medicines has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Praxis Precision Medicines this week, compared to 1 article on an average week.Search Interest10 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,600.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of Praxis Precision Medicines is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Praxis Precision Medicines are expected to grow in the coming year, from ($1.77) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Praxis Precision Medicines (NASDAQ:PRAX) StockPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.Read More PRAX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRAX Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Coverage Initiated by Analysts at Truist FinancialSeptember 19, 2023 | msn.comTruist Securities Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy RecommendationSeptember 22, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 7, 2023 | finance.yahoo.comPraxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment ConferenceAugust 31, 2023 | finance.yahoo.comPraxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy CongressAugust 28, 2023 | finance.yahoo.comPraxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International CongressAugust 17, 2023 | finance.yahoo.comBillionaire Steve Cohen Loads Up on These 2 ‘Strong Buy’ Penny Stocks — Here’s Why Wall Street Sees Over 500% Upside PotentialAugust 11, 2023 | finance.yahoo.comThe past year for Praxis Precision Medicines (NASDAQ:PRAX) investors has not been profitableSeptember 22, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 10, 2023 | msn.comHC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy RecommendationAugust 10, 2023 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Praxis Precision MedicineAugust 9, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Praxis Precision Medicines (PRAX)August 9, 2023 | finance.yahoo.comPraxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comPraxis reports positive data from study of focal epilepsy drugAugust 8, 2023 | finance.yahoo.comPraxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for UlixacaltamideAugust 7, 2023 | finance.yahoo.comPraxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 StudyAugust 3, 2023 | finance.yahoo.comPraxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare ConferenceJuly 24, 2023 | msn.comPraxis Precision Medicines: Long List Of Failures And Mixed DataJuly 14, 2023 | finance.yahoo.comFollowing a 63% decline over last year, recent gains may please Praxis Precision Medicines, Inc. (NASDAQ:PRAX) institutional ownersJuly 6, 2023 | msn.comPraxis Precision Medicines (PRAX) Price Target Decreased by 11.23% to 8.26June 28, 2023 | nasdaq.comCohen's Point72 Boosts Stake in Praxis Precision Medicines Ahead of Phase 3 TrialsJune 26, 2023 | benzinga.comSteven A. Cohen Discloses 8.9% Passive Stake In Praxis Precision MedicinesJune 22, 2023 | finanznachrichten.dePraxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate PrioritiesJune 22, 2023 | finance.yahoo.comPraxis Precision Medicines Announces Closing of Financing and Reiterates Corporate PrioritiesJune 20, 2023 | markets.businessinsider.comWedbush Sticks to Their Hold Rating for Praxis Precision Medicines (PRAX)June 17, 2023 | msn.comPraxis Precision Medicines stock dips on pricing $59.1M securities offeringJune 16, 2023 | finance.yahoo.comPraxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public OfferingSee More Headlines Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAX Company Calendar Last Earnings8/09/2023Today9/21/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRAX CUSIPN/A CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees109Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.50 High Stock Price Forecast$10.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+470.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-214,030,000.00 Net MarginsN/A Pretax Margin-10,716.19% Return on Equity-178.60% Return on Assets-129.68% Debt Debt-to-Equity RatioN/A Current Ratio5.31 Quick Ratio5.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book0.92Miscellaneous Outstanding Shares128,540,000Free Float122,242,000Market Cap$191.52 million OptionableNot Optionable Beta2.93 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Marcio Souza M.B.A. (Age 44)Pres, CEO & Director Comp: $1.04MMr. Timothy Edwin Kelly (Age 49)CFO & Treasurer Comp: $633.49kDr. Steven Petrou B.Sc. (Hons.)Ph.D., Co-Founder & Chief Scientific OfficerLauren MastrocolaVP of Fin. & Principal Accounting OfficerDr. Karl Hansen Ph.D.Chief Technical Operations OfficerAlex KaneVP of Investor Relations & Corp. CommunicationsMr. Alex Nemiroff J.D. (Age 44)Gen. Counsel & Sec. Ms. Kelly McCueChief People OfficerMs. Alyssa J. S. Wyant (Age 48)Chief Regulatory & Quality Officer Ms. Megan T. Sniecinski (Age 41)Chief Bus. Officer More ExecutivesKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLOmerosNASDAQ:OMEREmergent BioSolutionsNYSE:EBSXOMANASDAQ:XOMAVaxxinityNASDAQ:VAXXView All CompetitorsInsiders & InstitutionsSphera Funds Management LTD.Bought 8,764,334 shares on 8/15/2023Ownership: 13.675%Silverarc Capital Management LLCBought 3,476,162 shares on 8/15/2023Ownership: 5.424%CIBC Asset Management IncBought 246,014 shares on 8/15/2023Ownership: 2.388%Goldman Sachs Group Inc.Sold 607,155 shares on 8/15/2023Ownership: 0.240%Y Intercept Hong Kong LtdBought 67,177 shares on 8/15/2023Ownership: 0.105%View All Insider TransactionsView All Institutional Transactions PRAX Stock - Frequently Asked Questions Should I buy or sell Praxis Precision Medicines stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRAX shares. View PRAX analyst ratings or view top-rated stocks. What is Praxis Precision Medicines' stock price forecast for 2023? 4 equities research analysts have issued 1-year price targets for Praxis Precision Medicines' stock. Their PRAX share price forecasts range from $7.00 to $10.00. On average, they expect the company's share price to reach $8.50 in the next year. This suggests a possible upside of 470.5% from the stock's current price. View analysts price targets for PRAX or view top-rated stocks among Wall Street analysts. How have PRAX shares performed in 2023? Praxis Precision Medicines' stock was trading at $2.38 at the beginning of 2023. Since then, PRAX shares have decreased by 37.4% and is now trading at $1.49. View the best growth stocks for 2023 here. When is Praxis Precision Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our PRAX earnings forecast. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) posted its earnings results on Wednesday, August, 9th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.17. The firm had revenue of $0.78 million for the quarter. When did Praxis Precision Medicines IPO? (PRAX) raised $126 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager. What is Praxis Precision Medicines' stock symbol? Praxis Precision Medicines trades on the NASDAQ under the ticker symbol "PRAX." Who are Praxis Precision Medicines' major shareholders? Praxis Precision Medicines' stock is owned by many different retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (16.46%), Cormorant Asset Management LP (14.82%), Sphera Funds Management LTD. (13.68%), VR Adviser LLC (8.28%), Silverarc Capital Management LLC (5.42%) and Acadian Asset Management LLC (2.41%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Praxis Precision Medicines' stock price today? One share of PRAX stock can currently be purchased for approximately $1.49. How much money does Praxis Precision Medicines make? Praxis Precision Medicines (NASDAQ:PRAX) has a market capitalization of $191.52 million. The company earns $-214,030,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. How many employees does Praxis Precision Medicines have? The company employs 109 workers across the globe. How can I contact Praxis Precision Medicines? Praxis Precision Medicines' mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The official website for the company is www.praxismedicines.com. The company can be reached via phone at 617-300-8460 or via email at investors@praxismedicines.com. This page (NASDAQ:PRAX) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.